Cost-effectiveness of 44 mcg subcutaneous interferon beta-1a (scIFNβ1a) and 30 mcg intramuscular interferon beta-1a (imIFNβ1a) using clinical endpoints of disease activity

被引：0
|
作者：
Phillips, A. L. [1 ]
Edwards, N. C. [2 ]
Locklear, J. C. [1 ]
机构：
[1] EMD Serono Inc, Rockland, MA USA
[2] Hlth Serv Consulting Corp, Boxboro, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P839
引用
收藏
页码：421 / 421
页数：1
相关论文
共 50 条
  • [1] Risk of Stroke in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon beta-1a (scIFNβ-1a)
    Sabido, Meritxell
    Venkatesh, Saritha
    Aldridge, Julie
    Gillett, Alan
    [J]. NEUROLOGY, 2018, 90
  • [2] Pregnancy Outcomes in Patients Exposed to Intramuscular Interferon beta-1a (IM IFNβ-1a)
    Tomczyk, Sylvie
    Sperling, Bjorn
    [J]. NEUROLOGY, 2013, 80
  • [3] A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a and Intramuscular Interferon Beta-1a for the Treatment of Relapsing Multiple Sclerosis
    Scott, Thomas
    Shang, Shulian
    Castrillo-Viguera, Carmen
    [J]. NEUROLOGY, 2017, 88
  • [4] Evolution of New Lesions and its Temporal Patterns in Patients with Clinically Isolated Syndrome (CIS) Treated with Subcutaneous Interferon beta-1a (scIFNβ-1a)
    Vrenken, Hugo
    de Vos, Marlieke
    Battaglini, Marco
    Nagtegaal, Gijs J.
    de Almeida Teixeira, Bernardo Correa
    Marhardt, Kurt
    de Stefano, Nicola
    Barkhof, Frederik
    [J]. NEUROLOGY, 2018, 90
  • [5] Pharmacokinetics and pharmacodynamics of interferon beta-1a (IFN beta-1a) in healthy volunteers after intravenous, subcutaneous or intramuscular administration
    Alam, J
    McAllister, A
    Scaramucci, J
    Jones, W
    Rogge, M
    [J]. CLINICAL DRUG INVESTIGATION, 1997, 14 (01) : 35 - 43
  • [6] A study of the effect of gender on interferon beta-1a (Avonex® 30 mcg) treatment in patients with multiple sclerosis
    Munschauer, FE
    Herndon, R
    Sandrock, AW
    Tsao, E
    Berkhoff, JE
    Stubbendick, A
    [J]. MULTIPLE SCLEROSIS, 2005, 11 : S78 - S78
  • [7] COST-EFFECTIVENESS ANALYSIS OF ALEMTUZUMAB IN COMPARISON WITH NATALIZUMAB, INTRAMUSCULAR INTERFERON BETA-1A, SUBCUTANEOUS INTERFERON BETA-1B, AND FINGOLIMOD FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN IRAN
    Taheri, S.
    Yousefi, N.
    Sahraian, M. A.
    Mehralian, G.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A723 - A723
  • [8] Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a
    Rudick, R. A.
    Pace, A.
    Rani, M. R. S.
    Hyde, R.
    Panzara, M.
    Appachi, S.
    Shrock, J.
    Maurer, S. L.
    Calabresi, P. A.
    Confavreux, C.
    Galetta, S. L.
    Lublin, F. D.
    Radue, E. -W.
    Ransohoff, R. M.
    [J]. NEUROLOGY, 2009, 72 (23) : 1989 - 1993
  • [9] Characteristics and clinical outcomes of older patients with ms treated with peginterferon beta-1a or intramuscular interferon beta-1a in ms paths
    Hua, L. H.
    Liao, S.
    Hersh, C.
    Fitzgerald, K.
    Altincatal, A.
    Naylor, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 519 - 520
  • [10] Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis
    Yang, Hongbo
    Duchesneau, Emilie
    Foster, Rebekah
    Guerin, Annie
    Ma, Esprit
    Thomas, Nina P.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (10) : 1056 - 1065
12345